Vivo Bio Tech Ltd (VIVOBIOT) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Vivo Bio Tech Ltd on NSE and BSE, with an AI summary of each filing.
Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve Vivo Bio Tech Ltd has informed ....
Intimation · 11 Nov 2026, 5:30 am
Vivo Bio Tech Board to Consider Q2 Results on 11th Nov'26 Vivo Bio Tech Limited has scheduled a Board of Directors meeting on 11th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the second quarter and half year ended 30th Sep'26. Consequently, the trading window for all designated persons, directors, promoters, and connected entities remains closed until 48 hours following the declaration of the financial results.
Please find enclosed
Others (Uncategorized) · 13 Oct 2026, 9:03 pm
Vivo Bio Tech Reports Fire Incident at Telangana Research Facility A fire broke out at Vivo Bio Tech's research facility in Gajwel, Telangana, on 13th Oct'26. The incident caused damage to laboratory infrastructure, scientific equipment, plant and machinery, and destroyed sponsor test items, samples, and pathology specimens across ongoing and future studies. No injuries or casualties were reported, and the fire is under control. The company is evaluating the full operational and financial impact while confirming that affected assets are adequately insured and claim processes are underway.
Please find Enclosed
Others (Uncategorized) · 10 Oct 2026, 11:04 pm
Vivo Bio Tech Reports Nil Physical Share Transfer Re-Lodgement Requests Vivo Bio Tech submitted its compliance report regarding shareholder requests for re-lodgement of physical share transfers for the period ended Sep'26, pursuant to SEBI circular guidelines. As confirmed by its Registrar and Share Transfer Agent, Aarthi Consultants, the company received, processed, approved, and rejected nil transfer requests during the month, maintaining a clean regulatory compliance status with zero pending physical share transfer activity.
Please find enclosed scrutinizer''s report for 39th AGM
Annual General Meeting · 01 Oct 2026, 12:31 am
Please find enclosed
Change in Management · 01 Oct 2026, 12:27 am
Vivo Bio Tech Concludes 39th AGM and Approves Director Re-Appointments Vivo Bio Tech Limited conducted its 39th AGM on 30th Sep'26 via video conferencing. Key resolutions transacted included the adoption of audited standalone and consolidated financial statements for the fiscal year ended 31st Mar'26. Shareholders considered the re-appointment of Mr. Kalyan Ram Mangipudi (retiring by rotation), alongside the re-appointment of Whole-time Directors Mr. Sri Kalyan Kompella (effective 3rd Nov'26 to 2nd Nov'31) and Dr. Sankaranarayanan Alangudi (effective 6th Jan'27 to 5th Jan'32), each for five-year terms. Final voting results will be disseminated on or before 3rd Oct'26.
Please find enclosed 39th AGM proceedings
Annual General Meeting · 01 Oct 2026, 12:25 am
Please find enclosed report on Re-lodgement of Transfer requesrs of Physical Shares.
Others (Uncategorized) · 10 Sept 2026, 11:52 pm
Vivo Bio Tech Reports Nil Physical Share Transfer Re-Lodgement Requests for Aug'26 Vivo Bio Tech Limited submitted its compliance report pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30th Jan'26. According to the report received from its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, the company recorded nil requests received, processed, approved, or rejected for the re-lodgement of physical share transfer requests during the month ended Aug'26 under the designated SEBI special window.
the company has processed the letters to the shareholders who have not registered their Email ID with the company/RTA/DP providing the web link of the annual report.
Annual Report · 09 Sept 2026, 9:43 pm
Please find enclosed Annual report for FY 2025-26
Others (Uncategorized) · 09 Sept 2026, 12:55 am
Please find enclosed 39th Annual General Meeting Notice.
Annual General Meeting · 09 Sept 2026, 12:47 am
Please find enclosed
Others (Uncategorized) · 25 Aug 2026, 12:53 am
Vivo Bio Tech: Convertible Warrants Expire Unexercised Vivo Bio Tech announced that 627,409 convertible equity warrants allotted to Dwight Technologies Private Limited have expired due to non-exercise. These warrants, part of a 25,00,000 warrant preferential issue on 24 Feb'25, were priced at Rs. 45 each. The non-conversion before the 24 Aug'26 expiry date averts potential equity dilution. The warrants were issued at a face value of Rs. 10 with a Rs. 35 premium.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Maxcell Communication India Pvt Ltd
Acquisition/ Disposal of Shares · 24 Aug 2026, 3:46 pm
Vivo Bio Tech: Promoter Group Member Sells 4.09% Stake Maxcell Communication India Private Limited, a promoter group entity of Vivo Bio Tech Ltd, sold 1,200,000 equity shares via an off-market transaction on Aug 21, '26. This sale represents 5.41% of the total share capital and 4.09% of the fully diluted share capital. Post-transaction, Maxcell Communication's holding in the company is nil. Before this sale, the promoter entity held a 5.41% stake. The total diluted share capital of Vivo Bio Tech post-sale stands at 29,323,111 shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dwight Technologies Pvt Ltd
Acquisition/ Disposal of Shares · 24 Aug 2026, 3:44 pm
Dwight Technologies Increases Stake in Vivo Bio Tech Dwight Technologies Private Limited, a non-promoter entity, acquired 12,00,000 equity shares of Vivo Bio Tech Limited (BSE: 511509) via an off-market transaction on Aug 21, '26. This purchase increased Dwight's holding from 18,72,561 shares (8.44%) to 30,72,561 shares (13.85%). On a diluted basis, its stake rose from 6.39% to 10.48%. The acquisition raises Dwight Technologies' total shareholding by 5.41% of Vivo Bio Tech's total voting capital, solidifying its position as a significant shareholder.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for P K L Solution Pvt Ltd
Acquisition/ Disposal of Shares · 24 Aug 2026, 3:43 pm
Vivo Bio Tech: Promoter Group Member Sells 2.7% Stake Promoter group entity P.K.L Solution Private Limited has disposed of 600,000 equity shares of Vivo Bio Tech Limited, representing 2.70% of total voting capital. The off-market transaction occurred on Aug 21, '26. Before the sale, P.K.L Solution held 600,000 shares (2.70% stake). Following the disposal, its holding in the target company is now nil. The total diluted share capital of Vivo Bio Tech post-transaction stands at 29,323,111 equity shares.
Please find enclosed
Change in Management · 23 Aug 2026, 1:13 am
Vivo Bio Tech Board Approves Key Director Re-appointments Vivo Bio Tech’s Board, in its meeting on 22 Aug '26, approved key leadership re-appointments. Mr. Sri Kalyan Kompella (Whole-time Director) was re-appointed for five years, effective 03 Nov '26 to 02 Nov '31. Dr. Sankaranarayanan Alangudi (Whole-time Director) was also re-appointed for a five-year term from 06 Jan '27 to 05 Jan '32. Additionally, the Board approved the re-appointment of Mr. Kalyan Ram Mangipudi (Whole-Time Director). The company's 39th AGM is scheduled for 30 Sep '26.
Please find enclosed
Others (Uncategorized) · 23 Aug 2026, 1:10 am
Vivo Bio Tech Approves Director Re-appointments Vivo Bio Tech's board, in its meeting on Aug 22, '26, approved key director re-appointments. Mr. Sri Kalyan Kompella was re-appointed as Whole-time Director for a five-year term from Nov 03, '26, to Nov 02, '31. Dr. Sankaranarayanan Alangudi was also re-appointed as Whole-time Director for five years, from Jan 06, '27, to Jan 05, '32. Additionally, the re-appointment of Mr. Kalyan Ram Mangipudi was approved. The company's 39th AGM will be held virtually on Sep 30, '26. All appointments are subject to shareholder approval.
Please find enclosed
Others (Uncategorized) · 22 Aug 2026, 12:34 am
Vivo Bio Tech: Promoter Warrants Expire, Reducing Dilution Risk Vivo Bio Tech announced that 810,000 promoter-held convertible equity warrants have expired unexercised. These warrants were part of a 1.2M issue on 21st Feb '25 at an issue price of ₹45 each. The non-conversion by the promoters, Kompella Lopa Mudra and Kompella Modini, before the 21st Aug '26 deadline avoids potential equity dilution. This represents 67.5% of the total warrants issued. The expiry signals that promoters did not infuse further capital at the predetermined price, a factor for market consideration.
Please find enclosed.
Others (Uncategorized) · 21 Aug 2026, 12:21 am
Vivo Bio Tech: Convertible Warrants Expire Unexercised Vivo Bio Tech announced that 483 convertible equity warrants, allotted to Antique Infotech Private Limited on Feb 20, 2025, have expired unexercised. These were part of a total 2.6M warrant issuance. The warrants, issued at Rs. 45 each (FV Rs. 10, Premium Rs. 35), expired on Aug 20, 2026, as they were not converted within the 18-month tenure. This expiry avoids potential equity dilution from this specific tranche.
Please find enclosed.
Financial Result · 14 Jul 2026, 1:19 am
Vivo Bio Tech Q1FY27 Net Profit Plummets 86% YoY Amid Rising Costs For Q1FY27 ended 30 Jun'26, Vivo Bio Tech's consolidated net profit fell 85.97% YoY to ₹18.76 lacs from ₹133.71 lacs, driven by higher employee and depreciation costs. Revenue from operations grew 14.13% YoY to ₹1,427.97 lacs. However, total expenses surged 25.31% YoY to ₹1,399.65 lacs, compressing margins. On a QoQ basis, the company swung to a profit from a loss of ₹516.27 lacs in the prior quarter, while revenue saw a marginal increase of 0.55%. Basic EPS stood at ₹0.08, down from ₹0.74 YoY.
Please find enclosed board meeting outcome
Outcome · 14 Jul 2026, 1:11 am
Vivo Bio Tech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lacs) ■ Revenue: 1,428 (+14.1% YoY | +0.6% QoQ) ■ EBITDA: 505 (-8.0% YoY | +0.0% QoQ) ■ EBITDA Margin (%): 35.4 (-849 bps YoY | -20 bps QoQ) ■ PAT: 18.8 (-86.0% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.08 (-89.2% YoY | Loss to Profit QoQ)
Please find enclosed
Others (Uncategorized) · 10 Jul 2026, 9:06 pm
Vivo Bio Tech Reports No Re-lodgement Requests for Physical Shares in Jun'26 As per a regulatory filing on 10th Jul'26, Vivo Bio Tech's Share Transfer Agent, Aarthi Consultants, reported receiving zero requests for the re-lodgement of physical share transfers for the month ended Jun'26. This is in compliance with the SEBI circular dated 30th Jan'26. Consequently, no requests were processed, approved, or rejected during the period. The disclosure indicates minimal activity related to physical share certificate transfers for the company.
Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/07/2026 ,inter alia, to consider and approve Please find enclosed
Intimation · 13 Jul 2026, 5:30 am
Vivo Bio Tech Sets Board Meeting to Approve Q1 FY27 Results Vivo Bio Tech has scheduled a Board of Directors meeting on Jul 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the first quarter ending Jun 30, 2026. In connection with this, the company has closed its trading window for all designated persons, which will remain in effect until Jul 15, 2026.
Please find enclosed revise board meeting outcome
Outcome · 30 Jun 2026, 12:14 am
Vivo Bio Tech Appoints New Company Secretary Amidst Key Management Reshuffle Vivo Bio Tech announced the appointment of Mr. Bhavish Vijayvargiya as the new Company Secretary and Compliance Officer, effective 24-Jun'26. This follows the resignation of the previous officer, Mr. A V Kiran, who is leaving to pursue other career opportunities. The decisions were made during a Board of Directors meeting held on 24-Jun'26, which commenced at 4:00 PM and concluded at 4:20 PM. A clarification was filed with the exchange on 29-Jun'26 to address the inadvertent omission of these meeting times.
Please find enclosed
Others (Uncategorized) · 24 Jun 2026, 11:40 pm
Vivo Bio Tech Appoints New Officer for Materiality Determination Vivo Bio Tech has appointed Mr. Bhavish Vijayvargiya, Company Secretary & Compliance Officer, as the key managerial personnel responsible for determining the materiality of information for stock exchange disclosures. This change is effective 24-Jun'26, following the cessation of Mr. A V Kiran from the role. Mr. Vijayvargiya will now be the authorized person for advising on disclosure requirements to the exchanges, a key corporate governance function.
Please find enclosed.
Change in Management · 24 Jun 2026, 10:12 pm
Vivo Bio Tech Appoints New Company Secretary Amid Resignation Vivo Bio Tech announced Mr. A V Kiran has resigned as Company Secretary & Compliance Officer, effective 24 Jun'26, to pursue other career opportunities. The Board has appointed Mr. Bhavish Vijayvargiya as the new Company Secretary and Compliance Officer, also effective 24 Jun'26. Mr. Vijayvargiya is an Associate Member of the Institute of Company Secretaries of India and has experience in corporate secretarial functions and compliance management. This change ensures continuity in the company's key managerial personnel.